Top

Published in:

Open Access 01-04-2016 | Preclinical study

A novel gene expression signature for bone metastasis in breast carcinomas

Authors: C. Dilara Savci-Heijink, Hans Halfwerk, Jan Koster, Marc J. van de Vijver

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Abstract

Metastatic cancer remains the leading cause of death for patients with breast cancer. To understand the mechanisms underlying the development of distant metastases to specific sites is therefore important and of potential clinical value. From 157 primary breast tumours of the patients with known metastatic disease, gene expression profiling data were generated and correlated to metastatic behaviour including site-specific metastasis, metastasis pattern and survival outcomes. We analysed gene expression signatures specifically associated with the development of bone metastases. As a validation cohort, we used a published dataset of 376 breast carcinomas for which gene expression data and site-specific metastasis information were available. 80.5 % of luminal-type tumours developed bone metastasis as opposed to 41.7 % of basal and 55.6 % of HER2-like tumours. A novel 15-gene signature identified 82.4 % of the tumours with bone metastasis, 85.2 % of the tumours which had bone metastasis as first site of metastasis and 100 % of the ones with bone metastasis only (p 9.99e−09), in the training set. In the independent dataset, 81.2 % of the positive tested tumours had known metastatic disease to the bone (p 4.28e−10). This 15-gene signature showed much better correlation with the development of bone metastases than previously identified signatures and was predictive in both ER-positive as well as in ER-negative tumours. Multivariate analyses revealed that together with the molecular subtype, our 15-gene expression signature was significantly correlated to bone metastasis status (p <0.001, 95 % CI 3.86–48.02 in the training set; p 0.001, 95 % CI 1.54–5.00 in the independent set). The 15 genes, APOPEC3B, ATL2, BBS1, C6orf61, C6orf167, MMS22L, KCNS1, MFAP3L, NIP7, NUP155, PALM2, PH-4, PGD5, SFT2D2 and STEAP3, encoded mainly membrane-bound molecules with molecular function of protein binding. The expression levels of the up-regulated genes (NAT1, BBS1 and PH-4) were also found to be correlated to epithelial to mesenchymal transition status of the tumour. We have identified a novel 15-gene expression signature associated with the development of bone metastases in breast cancer patients. This bone metastasis signature is the first to be identified using a supervised classification approach in a large series of patients and will help forward research in this area towards clinical applications.

Available only for authorised users

Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, Stamps AC, Herath A, Sim E, O’Hare MJ, Harris AL, Terrett JA (2003) Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 1:826–835PubMed

Aerbajinai W, Giattina M, Lee YT, Raffeld M, Miller JL (2003) The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. Blood 102:712–717. doi:10.1182/blood-2002-11-3324 CrossRefPubMed

Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399–1405PubMed

Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864–870. doi:10.1038/nature03482 CrossRefPubMed

Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R (2004) Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 6:R252–R263. doi:10.1186/bcr784 CrossRefPubMedPubMedCentral

Bos PD, Nguyen DX, Massague J (2010) Modeling metastasis in the mouse. Curr Opin Pharmacol 10:571–577. doi:10.1016/j.coph.2010.06.003 CrossRefPubMedPubMedCentral

Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009. doi:10.1038/nature08021 CrossRefPubMedPubMedCentral

Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366–370. doi:10.1038/nature11881 CrossRefPubMedPubMedCentral

Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45:977–983. doi:10.1038/ng.2701 CrossRefPubMedPubMedCentral

10.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572. doi:10.1038/nrc865 CrossRefPubMed

11.

Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3:e47. doi:10.1371/journal.pmed.0030047 CrossRefPubMedPubMedCentral

12.

Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ (2011) Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 178:1221–1232. doi:10.1016/j.ajpath.2010.11.076 CrossRefPubMedPubMedCentral

13.

Coulouarn C, Derambure C, Lefebvre G, Daveau R, Hiron M, Scotte M, Francois A, Daveau M, Salier JP (2005) Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition. J Hepatol 42:860–869. doi:10.1016/j.jhep.2005.01.027 CrossRefPubMed

14.

Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O’Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005. doi:10.1038/nature08989 CrossRefPubMedPubMedCentral

15.

Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, Rimm DL (2006) Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12:6459–6468. doi:10.1158/1078-0432.CCR-06-1383 CrossRefPubMed

16.

Drukker CA, van Tinteren H, Schmidt MK, Rutgers EJ, Bernards R, van de Vijver MJ, Van’t Veer LJ (2014) Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 143:587–592. doi:10.1007/s10549-013-2831-4 CrossRefPubMedPubMedCentral

17.

Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0 CrossRef

18.

Endo Y, Yamashita H, Takahashi S, Sato S, Yoshimoto N, Asano T, Hato Y, Dong Y, Fujii Y, Toyama T (2014) Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer 14:990. doi:10.1186/1471-2407-14-990 CrossRefPubMedPubMedCentral

19.

Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33. doi:10.1038/nrg1748 CrossRefPubMed

20.

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458. doi:10.1038/nrc1098 CrossRefPubMed

21.

Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL (2011) The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Res 13:R16. doi:10.1186/bcr2825 CrossRefPubMedPubMedCentral

22.

Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123:4195–4200. doi:10.1242/jcs.023820 CrossRefPubMedPubMedCentral

23.

Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL (2013) Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem 288:10819–10829. doi:10.1074/jbc.M112.442939 CrossRefPubMedPubMedCentral

24.

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52. doi:10.1002/cncr.11859 CrossRefPubMed

25.

Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed

26.

Groger CJ, Grubinger M, Waldhor T, Vierlinger K, Mikulits W (2012) Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One 7:e51136. doi:10.1371/journal.pone.0051136 CrossRefPubMedPubMedCentral

27.

Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132:523–535. doi:10.1007/s10549-011-1619-7 CrossRefPubMedPubMedCentral

28.

Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47. doi:10.1038/nrc704 CrossRefPubMed

29.

Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I et al (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556–2566PubMed

30.

Hu G, Kang Y, Wang XF (2009) From breast to the brain: unraveling the puzzle of metastasis organotropism. J Mol Cell Biol 1:3–5. doi:10.1093/jmcb/mjp005 CrossRefPubMed

31.

Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE (1999) STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523–14528CrossRefPubMedPubMedCentral

32.

Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326:1216–1219. doi:10.1126/science.1176009 CrossRefPubMedPubMedCentral

33.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549CrossRefPubMed

34.

Komatsu A, Nagasaki K, Fujimori M, Amano J, Miki Y (2008) Identification of novel deletion polymorphisms in breast cancer. Int J Oncol 33:261–270PubMed

35.

Korkmaz CG, Korkmaz KS, Kurys P, Elbi C, Wang L, Klokk TI, Hammarstrom C, Troen G, Svindland A, Hager GL, Saatcioglu F (2005) Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 24:4934–4945. doi:10.1038/sj.onc.1208677 CrossRefPubMed

36.

Landemaine T, Jackson A, Bellahcene A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretiere JM, Ricevuto E, Nogues C, Briffod M, Bieche I, Cherel P, Garcia T, Castronovo V, Teti A, Lidereau R, Driouch K (2008) A six-gene signature predicting breast cancer lung metastasis. Cancer Res 68:6092–6099. doi:10.1158/0008-5472.CAN-08-0436 CrossRefPubMed

37.

Laurieri N, Crawford MH, Kawamura A, Westwood IM, Robinson J, Fletcher AM, Davies SG, Sim E, Russell AJ (2010) Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1, a potential breast cancer biomarker. J Am Chem Soc 132:3238–3239. doi:10.1021/ja909165u CrossRefPubMed

38.

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891–906. doi:10.1016/j.cell.2009.10.027 CrossRefPubMedPubMedCentral

39.

Liu F, Stanton JJ, Wu Z, Piwnica-Worms H (1997) The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 17:571–583CrossRefPubMedPubMedCentral

40.

Long J, Delahanty RJ, Li G, Gao YT, Lu W, Cai Q, Xiang YB, Li C, Ji BT, Zheng Y, Ali S, Shu XO, Zheng W (2013) A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 105:573–579. doi:10.1093/jnci/djt018 CrossRefPubMedPubMedCentral

41.

Lorusso G, Ruegg C (2012) New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 22:226–233. doi:10.1016/j.semcancer.2012.03.007 CrossRefPubMed

42.

Maia CJ, Socorro S, Schmitt F, Santos CR (2008) STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland. Endocrine 34:108–116. doi:10.1007/s12020-008-9113-7 CrossRefPubMed

43.

Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massague J (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104:6740–6745. doi:10.1073/pnas.0701138104 CrossRefPubMedPubMedCentral

44.

Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Investig 115:44–55. doi:10.1172/JCI22320 CrossRefPubMedPubMedCentral

45.

Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van’t Veer LJ, Rutgers EJ (2010) Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 17:1406–1413. doi:10.1245/s10434-009-0902-x CrossRefPubMed

46.

Nuyten DS, Hastie T, Chi JT, Chang HY, van de Vijver MJ (2008) Combining biological gene expression signatures in predicting outcome in breast cancer: an alternative to supervised classification. Eur J Cancer 44:2319–2329. doi:10.1016/j.ejca.2008.07.015 CrossRefPubMed

47.

O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29. doi:10.1634/theoncologist.10-90003-20 CrossRefPubMed

48.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167. doi:10.1200/JCO.2008.18.1370 CrossRefPubMedPubMedCentral

49.

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361CrossRefPubMed

50.

Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11. doi:10.1186/1741-7015-6-11 CrossRefPubMedPubMedCentral

51.

Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45:970–976. doi:10.1038/ng.2702 CrossRefPubMedPubMedCentral

52.

Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ (2015) Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 150:547–557. doi:10.1007/s10549-015-3352-0 CrossRefPubMedPubMedCentral

53.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. doi:10.1038/nrc1187 CrossRefPubMed

54.

Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, Gray KP, Foekens JA, Harris RS, Martens JW (2014) Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer 5:405–413. doi:10.1007/s12672-014-0196-8 CrossRefPubMedPubMedCentral

55.

Sledge GW Jr, Hu P, Falkson G, Tormey D, Abeloff M (2000) Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 18:262–266PubMed

56.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMedPubMedCentral

57.

Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol 64:170–179. doi:10.1124/mol.64.1.170 CrossRefPubMed

58.

Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF (2011) RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One 6:e17031. doi:10.1371/journal.pone.0017031 CrossRefPubMedPubMedCentral

59.

Tiang JM, Butcher NJ, Minchin RF (2015) Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med 4:565–574. doi:10.1002/cam4.415 CrossRefPubMedPubMedCentral

60.

Tiang JM, Butcher NJ, Minchin RF (2010) Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 393:95–100. doi:10.1016/j.bbrc.2010.01.087 CrossRefPubMed

61.

van de Vijver MJ, He YD, van’t Veer LI, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van de Vijver, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. doi:10.1056/NEJMoa021967 CrossRefPubMed

62.

Wottawa M, Leisering P, Ahlen M, Schnelle M, Vogel S, Malz C, Bordoli MR, Camenisch G, Hesse A, Napp J, Alves F, Kristiansen G, Farhat K, Katschinski DM (2013) Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-beta1 processing. Int J Cancer 132:2787–2798. doi:10.1002/ijc.27982 CrossRefPubMed

63.

Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, Kelley MC, Zheng W, Long J (2013) APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 34:2240–2243. doi:10.1093/carcin/bgt185 CrossRefPubMedPubMedCentral

64.

Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC, Aronow BJ, Lorenz JN, Dorn GW 2nd (2002) Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 8:725–730. doi:10.1038/nm719 PubMed

65.

Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens JA, Massague J (2013) Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154:1060–1073. doi:10.1016/j.cell.2013.07.036 CrossRefPubMedPubMedCentral

66.

Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16:67–78. doi:10.1016/j.ccr.2009.05.017 CrossRefPubMedPubMedCentral

Title: A novel gene expression signature for bone metastasis in breast carcinomas
Authors: C. Dilara Savci-Heijink
Hans Halfwerk
Jan Koster
Marc J. van de Vijver
Publication date: 01-04-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3741-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis

Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis

Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer